Triazolam: monitored release in the United Kingdom.
1 A monitored release for triazolam was carried out in the United Kingdom during 1979. Three thousand and ten patients were involved--approximately one-third were males and two-thirds were females. 2 The majority of patients (71.3%) took 0.25 mg triazolam: 24.1% took 0.125 mg and only 4.4% took 0.5 mg and above. There were no differences between the sexes, but there were differences according to age. In the group over 60 y, 45.4% took 0.25 mg and 50.7% took 0.125 mg. 3 The majority of patients (84.7%) reported an adequate night's sleep, and the overall incidence of side effects in patients taking the drug was 12.2%.
D000293:Adolescent; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D014229:Triazolam / Q000009:adverse effects / Q000627:therapeutic use*; D006113:United Kingdom
D014151:Anti-Anxiety Agents; D014229:Triazolam